Visual Features in Alzheimer’s Disease: From Basic Mechanisms to Clinical Overview
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is the leading cause of dementia worldwide. It compromises patients’ daily activities owing to progressive cognitive deterioration, which has elevated direct and indirect costs. Although AD has several risk factors, aging is considered the most important. Unfortunately, clinical diagnosis is usually performed at an advanced disease stage when dementia is established, making implementation of successful therapeutic interventions difficult. Current biomarkers tend to be expensive, insufficient, or invasive, raising the need for novel, improved tools aimed at early disease detection. AD is characterized by brain atrophy due to neuronal and synaptic loss, extracellular amyloid plaques composed of amyloid-beta peptide (A β), and neurofibrillary tangles of hyperphosphorylated tau protein. The visual system and central nervous system share many functional components. Thus, it is plausible that damage induced by A β, tau, and neuroinflammation may be observed in visual components such as the retina, even at an early disease stage. This underscores the importance of implementing ophthalmological examinations, less invasive and expensive than other biomarkers, as useful measures to assess disease progression and severity in individuals with or at risk of AD. Here, we review functional and morphological changes of the retina and visual pathway in AD from pathophysiological and clinical perspectives.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Scheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125
Jack, C. R., Albert, M. S., Knopman, D. S., McKhann, G. M., Sperling, R. A., Carrillo, M. C., Thies, B., & Phelps, C. H. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.004 · Cited by 2,042 · cited 1×
“According to the US National Institute on AgingAlzheimer’s Association workgroup, there are three different stages of AD: preclinical AD (presymptomatic with early AD-related brain changes observed by neuroimaging or other biomarker studies such as amyloid and tau studies in cerebrospinal fluid (CSF)), mild cognitive…”
MethodThe Cellular Phase of Alzheimer’s Disease
De Strooper, B., & Karran, E. (2016) · Cell · doi:10.1016/j.cell.2015.12.056 · Cited by 1,990
Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease
Kisler, K., Nelson, A. R., Montagne, A., & Zlokovic, B. V. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.48 · Cited by 1,243
Glial regulation of the cerebral microvasculature
Iadecola, C., & Nedergaard, M. (2007) · Nature Neuroscience · doi:10.1038/nn2003 · Cited by 1,153
Koronyo-Hamaoui, M., Koronyo, Y., Ljubimov, A. V., Miller, C. A., Ko, M. K., Black, K. L., Schwartz, M., & Farkas, D. L. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2010.06.020 · Cited by 672
Propagation of Tau aggregates and neurodegeneration
Goedert, M., Eisenberg, D. S., & Crowther, R. A. (2017) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-072116-031153 · Cited by 632 · cited 2×
“Some studies in transgenic mice have even reported earlier appearance of plaques in the retina than brain [42].”
BackgroundStrategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers
Frisoni, G. B., Boccardi, M., Barkhof, F., Blennow, K., Cappa, S., Chiotis, K., Démonet, J.-F., Garibotto, V., Giannakopoulos, P., Gietl, A., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30159-x · Cited by 626
The molecular bases of Alzheimer’s disease and other neurodegenerative disorders
Maccioni, R. B., Muñoz, J. P., & Barbeito, L. (2001) · Archives of Medical Research · doi:10.1016/s0188-4409(01)00316-2 · Cited by 474 · cited 10×
“These cellular changes are related with the presence of Aβ-plaques and NFT [70].”
BackgroundInfluentialApolipoprotein E in Alzheimer's Disease: An Update
Yu, J.-T., Tan, L., & Hardy, J. (2014) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-071013-014300 · Cited by 394 · cited 1×
“ApoE protein is mainly expressed in the brain on astrocytes, but also in microglia, neurons, pericytes, smooth muscle cells, and brain endothelial cells [85].”
BackgroundInnovative diagnostic tools for early detection of Alzheimer's disease
Laske, C., Sohrabi, H. R., Frost, S. M., López-de-Ipiña, K., Garrard, P., Buscema, M., Dauwels, J., Soekadar, S. R., Mueller, S., Linnemann, C., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.06.004 · Cited by 316
Parallel findings in age-related macular degeneration and Alzheimer’s disease
Ohno-Matsui, K. (2011) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2011.02.004 · Cited by 280 · cited 4×
“Aβ1–42 interacts with different drusen components, including complement proteins (HF1, C3b/iC3b, and C5), interleukins (IL-1β, IL-8, and IL-33), and lipids (cholesterol and phosphatidylcholine) to form mature Aβ fibrils, which compose the shell of amyloid vesicles [43, 82].”
BackgroundInfluentialThe role of APOE in cerebrovascular dysfunction
Tai, L. M., Thomas, R., Marottoli, F. M., Koster, K. P., Kanekiyo, T., Morris, A. W. J., & Bu, G. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1547-z · Cited by 231 · cited 1×
“ApoE is involved in the transport of cholesterol and triglycerides and is considered one of the most important risk factors for development of AD [84].”
BackgroundLuibl, V. (2006) · Journal of Clinical Investigation · doi:10.1172/jci25843 · Cited by 203 · cited 3×
““Drusen” in the retina are deposits of insoluble cellular debris and lipids localized beneath the RPE and inner collagenous layer of Bruch’s membrane (BM) [71].”
BackgroundThe potential role of amyloid in the pathogenesis of age-related macular degeneration
Yoshida, T. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24635 · Cited by 202
Transgenic Mouse Model of Tau Pathology in Astrocytes Leading to Nervous System Degeneration
Forman, M. S., Lal, D., Zhang, B., Dabir, D. V., Swanson, E., Lee, V. M.-Y., & Trojanowski, J. Q. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.0081-05.2005 · Cited by 198 · cited 1×
“Ultimately, accumulation of Aβ peptides may trigger intracellular signaling for tau hyperphosphorylation, with formation of tau oligomers and NFT [11, 14] leading to neuronal degeneration [41].”
BackgroundOcular changes in TgF344-AD rat model of Alzheimer's disease
Tsai, Y., Lu, B., Ljubimov, A. V., Girman, S., Ross-Cisneros, F. N., Sadun, A. A., Svendsen, C. N., Cohen, R. M., & Wang, S. (2014) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.13-12888 · Cited by 153
Krasodomska, K., Lubiński, W., Potemkowski, A., & Honczarenko, K. (2010) · Documenta Ophthalmologica · doi:10.1007/s10633-010-9238-x · Cited by 127 · cited 3×
“Most studies show decreased amplitudes and time delays, mainly in N35, P50, and N95 components, in PERG of patients with AD [140, 189].”
BackgroundResultVision function abnormalities in Alzheimer disease
Tzekov, R., & Mullan, M. (2014) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2013.10.002 · Cited by 94 · cited 1×
“These alterations include decreased visual acuity, with difficulties in writing and reading [154] increasing along with disease progression [139, 155, 156].”
BackgroundAskarova, S., Yang, X., Sheng, W., Sun, G. Y., & Lee, J. C.-M. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.09.038 · Cited by 92
Melanopsin-expressing retinal ganglion cells: implications for human diseases
La Morgia, C., Ross-Cisneros, F. N., Hannibal, J., Montagna, P., Sadun, A. A., & Carelli, V. (2011) · Vision Research · doi:10.1016/j.visres.2010.07.023 · Cited by 84
Baker-Nigh, A. T., Mawuenyega, K. G., Bollinger, J. G., Ovod, V., Kasten, T., Franklin, E. E., Liao, F., Jiang, H., Holtzman, D., Cairns, N. J., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.721779 · Cited by 54 · cited 1×
“Furthermore, the risk of amyloidosis in AD is suggested to be related to the interaction between ApoE, aging, and amyloid burden [88].”
BackgroundFoldi, N. S., White, R. E. C., & Schaefer, L. A. (2005) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1319 · Cited by 51 · cited 1×
“In this regard, the use of cholinergic drugs such as donepezil leads to improvement in visual selective attention [119].”
Background
Cited by
Sphingolipids in neuroinflammation: a potential target for diagnosis and therapy
Lee, J. Y., Jin, H. K., & Bae, J.-S. (2020) · BMB Reports · doi:10.5483/bmbrep.2020.53.1.278 · Cited by 80
“intra-cellular A plaques and hyperphosphorylated tau (40, 41).”
BackgroundAging-associated sensory decline and Alzheimer’s disease
Hong, S., Baek, S.-H., Lai, M. K. P., Arumugam, T. V., & Jo, D.-G. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00776-y · Cited by 76
Pathophysiology of Alzheimer’s Disease
Yarns, B. C., Holiday, K. A., Carlson, D. M., Cosgrove, C. K., & Melrose, R. J. (2022) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2022.07.003 · Cited by 68
Metadata
- Authors
- Cerquera-Jaramillo, M. A., Nava-Mesa, M. O., González-Reyes, R. E., Tellez-Conti, C., & de-la-Torre, A.
- Venue
- Neural Plasticity
- Publisher
- Wiley
- Published
- 2018-10-14
- Volume
- 2018
- Pages
- 1-21
- ISSN
- 1687-5443 (ISSN-L)
- 2090-5904
- OpenAlex
- W2897880788
- Cited by
- 53
- References
- 23
- FWCI
- 4.51
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.